Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
13
×
Tags
biotech
13
×
life sciences
national blog main
13
×
national top stories
san francisco top stories
13
×
fda
san francisco blog main
boston blog main
boston top stories
clinical trials
new york top stories
indiana blog main
indiana top stories
national
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
eli lilly
cancer
genentech
novartis
drugs
europe top stories
roche
amgen
biogen
boston
deals
What
fda
13
×
drug
approval
bio
medicines
new
roundup
won
approved
cancer
drugs
friday
medicine
oral
patients
therapy
blueprint
class
companies
decades
developed
marketing
migraine
news
regulatory
ret
roche
time
activity
address
agency
ago
ahead
aimmune
allergy
alnylam
amgen
approvals
approve
approves
Language
unset
Current search:
photo
×
fda
×
" san francisco top stories "
×
biotech
×
" national blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines